🇺🇸 FDA

Intelligence Platform

Patents

Browse 81 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12391765

Methods and materials for assessing response to plasmablast- and plasma cell-depleting the

Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12364661

Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and tr

The Regents of the University of California · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297186

Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

AGOMAB SPAIN, S.L.U. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-i

Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240914

Antibody against factor XIa in activated form of coagulant factor XI, preparation method t

MAB-LEGEND BIOTECH CO., LTD. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12133884

Methods of substituting pathogenic amino acids using programmable base editor systems

Beam Therapeutics Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129307

HER-2 binding antibodies

MAB Discovery GmbH · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084504

Anti-MET antibodies and uses thereof

AGOMAB THERAPEUTICS · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018074

Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases

CHEMOMAB LTD. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11904017

Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896617

Polynucleotides encoding rituximab-resistant chimeric antigen receptors

Allogene Therapeutics, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884731

Vedolizumab for the treatment of fistulizing Crohn's disease

Takeda Pharmaceutical Company Limited · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851671

Programmable assembly of virus composites for receptor-targeted gene delivery

Regents of the University of Minnesota · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834507

Anti-MET agonist antibody for use in the treatment of colorectal cancer

AGOMAB THERAPEUTICS · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11702478

Agonistic CD40 antibodies

MAB Discovery GmbH · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11647776

Extract, consumable product and method for enriching bioactive metabolite in an extract

Brightseed, Inc. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613586

Methods and materials for assessing response to plasmablast- and plasma cell-depleting the

Takeda Pharmaceutical Company Limited · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491231

Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the as

Northwestern University · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464869

Non-adult human dosing of brentuximab vedotin

Takeda Pharmaceutical Company Limited · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439585

Programmable pharmaceutical compositions for chrono drug release

Amneal Complex Products Research LLC · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433025

Oil foamable carriers and formulations

Vyne Therapeutics Inc. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11365246

Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases

CHEMOMAB LTD. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352432

Antibodies specifically binding to human IL-1R7

MAB Discovery GmbH · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229702

High concentration formulations of adalimumab

Coherus BioSciences, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted